Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis (PSTELLAR)

This study has been completed.
Information provided by (Responsible Party):
Janssen Biotech, Inc. Identifier:
First received: March 8, 2012
Last updated: December 9, 2015
Last verified: December 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2015
  Primary Completion Date: May 2015 (Final data collection date for primary outcome measure)